Heart Failure Society of America Annual Scientific Meeting 2026

HFSA Annual Scientific Meeting 2026 | Advanced Heart Failure, HFrEF, HFpEF, GDMT, Cardiogenic Shock, LVAD, Heart Transplantation, Cardiomyopathies, Cardiorenal-Metabolic Medicine & Late-Breaking Clinical Trials

The Heart Failure Society of America Annual Scientific Meeting 2026 is a multidisciplinary cardiovascular educational conference focused on the prevention, diagnosis, treatment, and long-term management of heart failure and related cardiac conditions. Organized by the Heart Failure Society of America (HFSA), the 2026 Annual Scientific Meeting brought together leading heart failure specialists, cardiologists, cardiovascular surgeons, researchers, pharmacists, nurses, advanced practice providers, and allied healthcare professionals. Held October 9–12, 2026, at the Phoenix Convention Center in Phoenix, Arizona, the meeting delivered scientific education spanning advanced heart failure, cardiac transplantation, cardiogenic shock, cardiac devices, cardiomyopathies, heart failure pharmacotherapy, and multidisciplinary cardiovascular care. The HFSA Annual Scientific Meeting 2026 program explored contemporary developments in guideline-directed medical therapy (GDMT), heart failure with reduced ejection fraction (HFrEF), mildly reduced ejection fraction (HFmrEF), preserved ejection fraction (HFpEF), cardiac amyloidosis, hypertrophic cardiomyopathy, cardiorenal-metabolic disease, ventricular assist devices, and emerging diagnostic and therapeutic technologies. The conference featured plenary presentations, late-breaking clinical research, expert debates, multidisciplinary sessions, scientific abstracts, case-based discussions, and practical educational activities. Additional topics included artificial intelligence in heart failure care, remote patient monitoring, cardiovascular genetics, cardio-oncology, health equity, prevention, implementation science, and improving clinical outcomes through coordinated team-based care.

Course Details

• Course: Heart Failure Society of America Annual Scientific Meeting 2026
• Abbreviation: HFSA ASM 2026
• Organizer: Heart Failure Society of America (HFSA)
• Dates: October 9–12, 2026
• Location: Phoenix, Arizona, USA
• Primary Venue: Phoenix Convention Center
• Additional Program Venue: Sheraton Phoenix Downtown
• Original Format: In-Person Scientific Meeting with On-Demand Access for Registered Attendees
• Duration: Four Days
• Primary Specialty: Cardiology / Heart Failure Medicine
• Additional Focus: Advanced Heart Failure, Transplant Cardiology, Cardiomyopathies, Cardiac Electrophysiology, Critical Care and Cardiovascular Research
• Language: English
• 2026 Program Committee Chair: Jennifer Thibodeau, MD, MSCS, FHFSA, FACC, FAHA
• Educational Methods: Plenary Sessions, Clinical Research, Scientific Abstracts, Debates, Workshops and Case Discussions
• Original Attendee On-Demand Access: Through January 7, 2027
• MedicalAmboss Digital File Inventory: Not Independently Verified

The original HFSA scientific meeting and any separately distributed educational materials should be treated as distinct offerings.

Target Audience

The conference is designed for healthcare professionals involved in the care of patients with heart failure and cardiomyopathy. The target audience includes:

• Heart Failure Cardiologists
• Advanced Heart Failure Specialists
• Transplant Cardiologists
• General Cardiologists
• Interventional Cardiologists
• Cardiac Electrophysiologists
• Cardiothoracic Surgeons
• Heart Transplant Surgeons
• Critical Care Physicians
• Internists
• Hospitalists
• Nephrologists
• Endocrinologists
• Pulmonologists
• Medical Geneticists
• Cardio-Oncology Specialists
• Palliative Care Physicians
• Cardiovascular Pharmacists
• Nurse Practitioners
• Physician Assistants
• Heart Failure Nurses
• Cardiology Fellows
• Advanced Heart Failure and Transplant Fellows
• Clinical Researchers
• Allied Healthcare Professionals

The meeting is particularly relevant to clinicians seeking updates on advanced heart failure therapeutics, mechanical circulatory support, cardiac transplantation, inherited cardiomyopathies, and clinical trial evidence.

Program Overview

Heart failure is a complex clinical syndrome associated with impaired cardiac function, cardiovascular and systemic comorbidities, recurrent hospitalizations, and substantial effects on patient quality of life. Contemporary management requires an understanding of medical treatments, cardiac devices, mechanical support, clinical monitoring, disease-specific therapies, and multidisciplinary care. The HFSA Annual Scientific Meeting 2026 addresses these challenges through a broad educational program. Major scientific and clinical areas include:

• Heart Failure with Reduced Ejection Fraction
• Heart Failure with Mildly Reduced Ejection Fraction
• Heart Failure with Preserved Ejection Fraction
• Guideline-Directed Medical Therapy
• Acute Decompensated Heart Failure
• Cardiogenic Shock
• Mechanical Circulatory Support
• Left Ventricular Assist Devices
• Heart Transplantation
• Cardiac Amyloidosis
• Hypertrophic Cardiomyopathy
• Cardiac Sarcoidosis
• Myocarditis
• Genetic Cardiomyopathies
• Cardiorenal Syndrome
• Metabolic Dysfunction
• SGLT2 Inhibitors
• GLP-1 Receptor Agonists
• Mineralocorticoid Receptor Antagonists
• Cardiac Resynchronization Therapy
• Implantable Cardioverter-Defibrillators
• Conduction System Pacing
• Catheter Ablation
• Remote Hemodynamic Monitoring
• Artificial Intelligence
• Heart Failure Prevention
• Health Equity
• Palliative Care
• Late-Breaking Clinical Research

The curriculum emphasizes connecting scientific advances with practical treatment decisions and patient-centered cardiovascular care.

Learning Objectives

Based on the educational scope of the 2026 program, participants should be better able to:

1. Implement contemporary guideline-directed medical therapy for patients with HFrEF, HFmrEF, and HFpEF.
2. Evaluate emerging pharmacological treatments and clinical trial findings relevant to heart failure management.
3. Assess and manage acute decompensated heart failure and cardiogenic shock using appropriate clinical monitoring and treatment strategies.
4. Review patient selection, perioperative considerations, and long-term management of mechanical circulatory support and heart transplantation.
5. Recognize important clinical features of cardiac amyloidosis, hypertrophic cardiomyopathy, cardiac sarcoidosis, myocarditis, and inherited cardiomyopathies.
6. Evaluate the relationship between cardiac, renal, and metabolic disease in contemporary heart failure care.
7. Review indications and clinical considerations for electrophysiological interventions and cardiac device therapies.
8. Assess developments involving remote monitoring, digital health, and artificial intelligence.
9. Integrate multidisciplinary care, health equity, and appropriate palliative care into heart failure management.
10. Interpret scientific research and apply relevant evidence to individualized clinical decision-making.

Comprehensive HFSA 2026 Scientific Program

The following sections organize the confirmed major educational themes of the original meeting. They are not presented as a complete lecture-by-lecture recording inventory.

Session I – Guideline-Directed Medical Therapy

Contemporary Management of HFrEF

Heart failure with reduced ejection fraction requires comprehensive medical treatment, appropriate risk assessment, and longitudinal care. Relevant topics include:

• HFrEF Diagnosis
• Guideline-Directed Medical Therapy
• ARNI Therapy
• ACE Inhibitors and ARBs
• Evidence-Based Beta-Blockers
• Mineralocorticoid Receptor Antagonists
• SGLT2 Inhibitors
• Medication Optimization
• Blood Pressure and Renal Function
• Treatment Tolerability
• Clinical Follow-Up

Heart Failure with Mildly Reduced Ejection Fraction

Relevant considerations include:

• HFmrEF Classification
• Clinical Phenotypes
• Comorbidity Assessment
• Pharmacological Treatment
• Clinical Evidence
• Patient Monitoring
• Long-Term Outcomes

Heart Failure with Preserved Ejection Fraction

HFpEF is a major focus of modern heart failure research. Relevant topics include:

• HFpEF Diagnosis
• Echocardiography
• Diastolic Function
• Exercise Intolerance
• Volume Management
• SGLT2 Inhibitors
• Obesity
• Hypertension
• Atrial Fibrillation
• Comorbidity Management
• Emerging Treatments

The educational emphasis is on treatment individualization and understanding the diversity of HFpEF clinical presentations.

Session II – Acute Decompensated Heart Failure and Cardiogenic Shock

Acute Decompensated Heart Failure

Important clinical considerations include:

• Volume Overload
• Congestion
• Diuretic Therapy
• Hemodynamic Assessment
• Renal Dysfunction
• Inpatient Management
• Decongestion Strategies
• Clinical Monitoring
• Hospital Discharge Planning

Cardiogenic Shock

Cardiogenic shock is a major cause of morbidity and mortality among patients with severe cardiac dysfunction. Relevant topics include:

• Cardiogenic Shock Recognition
• Hemodynamic Profiles
• Risk Stratification
• Vasoactive Medications
• Invasive Hemodynamic Monitoring
• Temporary Mechanical Circulatory Support
• Multidisciplinary Shock Teams
• Treatment Escalation
• Clinical Outcomes

The scientific program addresses contemporary approaches to advanced acute heart failure care.

Session III – Mechanical Circulatory Support

Temporary Mechanical Circulatory Support

Temporary mechanical support may be considered in selected patients with severe hemodynamic compromise. Important concepts include:

• Intra-Aortic Balloon Pump
• Percutaneous Ventricular Assist Devices
• VA-ECMO
• Hemodynamic Support
• Device Selection
• Vascular Complications
• Patient Monitoring
• Treatment Escalation

Durable Left Ventricular Assist Devices

Durable mechanical circulatory support is relevant to patients with advanced heart failure. Important considerations include:

• LVAD Candidate Selection
• Advanced Heart Failure Assessment
• Surgical Implantation
• Anticoagulation
• Right Ventricular Failure
• Device-Related Infection
• Pump Thrombosis
• Gastrointestinal Bleeding
• Quality of Life
• Long-Term Follow-Up

The program includes scientific research relevant to device treatment and patient outcomes.

Session IV – Heart Transplantation

Advanced Heart Failure and Transplant Cardiology

Heart transplantation remains an important treatment option for selected patients with advanced heart failure. Relevant educational areas include:

• Transplant Candidate Evaluation
• Heart Transplant Listing
• Recipient Risk Assessment
• Donor Considerations
• Organ Allocation
• Immunosuppression
• Graft Rejection
• Infection Prevention
• Cardiac Allograft Vasculopathy
• Long-Term Transplant Management

Treatment Sequencing in Advanced Heart Failure

The 2026 meeting includes research relevant to treatment sequencing, particularly the relationship between mechanical support and heart transplantation. Clinical considerations include patient selection, expected outcomes, risk assessment, and timing of intervention.

Session V – Cardiomyopathies and Infiltrative Heart Disease

Cardiac Amyloidosis

Important topics include:

• Transthyretin Amyloid Cardiomyopathy
• AL Amyloidosis
• Diagnostic Testing
• Cardiac Imaging
• Biomarkers
• Disease-Specific Treatment
• Prognosis
• Clinical Monitoring

Hypertrophic Cardiomyopathy

Relevant subjects include:

• Obstructive HCM
• Nonobstructive HCM
• Genetic Evaluation
• Cardiac Imaging
• Exercise Capacity
• Sudden Cardiac Death Risk
• Myosin Inhibitors
• Emerging Clinical Trials

Additional Cardiomyopathies

Other clinically important topics include:

• Cardiac Sarcoidosis
• Myocarditis
• Inherited Cardiomyopathies
• Dilated Cardiomyopathy
• Arrhythmogenic Cardiomyopathy
• Genetic Counseling
• Diagnostic Imaging

The educational emphasis is on recognizing disease-specific mechanisms and selecting appropriate investigations and treatment approaches.

Session VI – Cardiorenal-Metabolic Medicine

Heart Failure and Kidney Disease

Cardiorenal interactions create important treatment challenges. Relevant considerations include:

• Cardiorenal Syndrome
• Chronic Kidney Disease
• Acute Kidney Injury
• Volume Management
• Diuretic Response
• Renal Function Monitoring
• SGLT2 Inhibitors
• Cardiovascular Risk

Obesity, Diabetes and Heart Failure

Important topics include:

• Type 2 Diabetes
• Obesity
• Metabolic Dysfunction
• SGLT2 Inhibitors
• GLP-1 Receptor Agonists
• Weight Management
• Cardiometabolic Risk
• HFpEF
• Individualized Treatment

The program emphasizes the growing importance of integrating metabolic and renal disease management into cardiovascular care.

Session VII – Electrophysiology and Cardiac Devices

Cardiac Resynchronization Therapy

Relevant areas include:

• CRT
• Patient Selection
• Ventricular Dyssynchrony
• Device Programming
• Clinical Outcomes
• Treatment Response

Implantable Cardioverter-Defibrillators

Important considerations include:

• Sudden Cardiac Death Prevention
• ICD Indications
• Ventricular Arrhythmias
• Device Selection
• Patient Risk Assessment
• Device Follow-Up

Conduction System Pacing and Catheter Ablation

Relevant topics include:

• His-Bundle Pacing
• Left Bundle Branch Area Pacing
• Physiological Pacing
• Atrial Fibrillation
• Catheter Ablation
• Rhythm Control
• Ventricular Function

These subjects reflect the relationship between electrophysiology and heart failure management.

Session VIII – Digital Health, Remote Monitoring and Artificial Intelligence

Remote Patient Monitoring

Important educational areas include:

• Remote Hemodynamic Monitoring
• Pulmonary Artery Pressure Monitoring
• Congestion Monitoring
• Digital Health
• Remote Clinical Assessment
• Early Detection of Deterioration
• Heart Failure Hospitalization Prevention

Artificial Intelligence in Heart Failure

Emerging research explores the use of artificial intelligence for:

• Risk Prediction
• Imaging Analysis
• Clinical Decision Support
• Patient Stratification
• Digital Monitoring
• Healthcare Workflows

These approaches require attention to clinical validation, reliability, bias, patient privacy, and clinician oversight.

Session IX – Health Equity and Multidisciplinary Care

Heart failure management is influenced by medical, social, economic, and healthcare delivery factors. Important themes include:

• Health Equity
• Access to Care
• Social Determinants of Health
• Medication Access
• Multidisciplinary Teams
• Nursing Care
• Pharmacist-Led Optimization
• Patient Education
• Shared Decision-Making
• Palliative Care
• Quality of Life
• Care Transitions

The program emphasizes comprehensive and patient-centered management.

Official Late-Breaking Clinical Research 2026

The following are examples of research included in the official HFSA 2026 scientific program. These are not a verified inventory of recordings supplied by MedicalAmboss.

REBALANCE Registry

Real-World Outcomes Following Baroreflex Activation Therapy

The REBALANCE Registry examines outcomes related to baroreflex activation therapy in patients with heart failure. Relevant research areas include:

• Baroreflex Activation Therapy
• Heart Failure Symptoms
• Device-Based Treatment
• Real-World Outcomes
• Patient Selection
• Clinical Follow-Up

ACACIA-HCM

Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy

The ACACIA-HCM trial examines aficamten in symptomatic nonobstructive hypertrophic cardiomyopathy. Relevant scientific themes include:

• Nonobstructive HCM
• Cardiac Myosin Inhibition
• Exercise Performance
• Patient Symptoms
• Clinical Trial Outcomes
• Treatment Safety

The official program also includes a prespecified analysis of exercise performance.

POSEIDON Study

Cardiovascular Inflammation Across the Heart Failure Spectrum

The POSEIDON research examines cardiovascular inflammation and associated biomarker profiles in patients with different heart failure phenotypes. Important concepts include:

• Inflammation
• Heart Failure Phenotypes
• Biomarker Profiles
• Cardiovascular Risk
• Clinical Characterization

C-MIC II and C-MIC III

Cardiac Microcurrent Therapy and Exercise Capacity

These studies examine cardiac microcurrent therapy in relation to exercise capacity and patient outcomes. Relevant subjects include:

• Device-Based Therapy
• Cardiopulmonary Exercise Testing
• Exercise Capacity
• Clinical Trial Analysis
• Treatment Outcomes

ATTRibute-CM Research

Serum Transthyretin and NT-proBNP as Prognostic Measures

This research evaluates the relationship between transthyretin and NT-proBNP measurements in patients with transthyretin amyloid cardiomyopathy. Relevant concepts include:

• ATTR Cardiomyopathy
• Cardiac Biomarkers
• NT-proBNP
• Prognostic Assessment
• Disease Monitoring

HF-TRACK Trial

Ambient Home Monitoring of Peripheral Edema

The HF-TRACK trial evaluates remote monitoring of peripheral edema and its relationship to heart failure events. Important areas include:

• Remote Monitoring
• Peripheral Edema
• Congestion Assessment
• Heart Failure Events
• Digital Health
• Home Monitoring

Acoramidis and Tafamidis Research

The scientific program includes studies comparing or evaluating treatments for transthyretin amyloid cardiomyopathy. Relevant topics include:

• ATTR-CM
• Acoramidis
• Tafamidis
• Treatment Effectiveness
• Clinical Outcomes
• Real-World Evidence

Major Topics Covered

• HFSA Annual Scientific Meeting 2026
• Heart Failure Society of America
• Heart Failure Medicine
• HFrEF
• HFmrEF
• HFpEF
• Guideline-Directed Medical Therapy
• Acute Decompensated Heart Failure
• Cardiogenic Shock
• Hemodynamic Monitoring
• Temporary Mechanical Circulatory Support
• LVAD
• Heart Transplantation
• Cardiac Amyloidosis
• Hypertrophic Cardiomyopathy
• Cardiac Sarcoidosis
• Myocarditis
• Genetic Cardiomyopathies
• Cardiorenal Syndrome
• Metabolic Heart Failure
• SGLT2 Inhibitors
• GLP-1 Receptor Agonists
• Mineralocorticoid Receptor Antagonists
• Cardiac Resynchronization Therapy
• ICD
• Conduction System Pacing
• Catheter Ablation
• Remote Patient Monitoring
• Artificial Intelligence in Cardiology
• Heart Failure Prevention
• Health Equity
• Palliative Care
• Late-Breaking Clinical Trials
• Cardiovascular Research

Advanced Heart Failure and Cardiovascular Outcomes

The HFSA 2026 scientific program emphasizes treatment approaches relevant to patients with advanced and refractory heart failure. These include pharmacotherapy, mechanical support, heart transplantation, device-based treatment, and coordinated multidisciplinary care.

Precision Medicine in Cardiomyopathy

Advances in genetic evaluation, imaging, biomarkers, and disease-specific therapies are influencing the diagnosis and management of cardiomyopathies. The conference includes research relevant to cardiac amyloidosis, hypertrophic cardiomyopathy, and other important myocardial disorders.

Emerging Pharmacology and Clinical Trials

The 2026 meeting includes scientific research evaluating established and emerging heart failure treatments. The program provides an opportunity to assess clinical trial design, treatment outcomes, patient selection, and potential implications for practice.

Patient-Centered Heart Failure Care

Heart failure management extends beyond medication and device therapy. The program addresses multidisciplinary care, health equity, quality improvement, remote monitoring, palliative care, and long-term patient outcomes.

Program Leadership

Jennifer Thibodeau, MD, MSCS, FHFSA, FACC, FAHA

2026 HFSA Annual Scientific Meeting Program Committee Chair The scientific meeting brings together researchers and clinicians from multiple cardiovascular specialties, with contributions from multidisciplinary heart failure teams.

Continuing Medical Education

The original HFSA Annual Scientific Meeting 2026 offered accredited continuing education opportunities for eligible participants. Available credit types and amounts depended on the specific activity, professional category, and participation requirements. Original registered attendees could access eligible on-demand sessions through January 7, 2027.

Important CME Notice

Purchasing separately distributed educational files through MedicalAmboss does not itself provide:

• Official HFSA CME Credits
• ABIM MOC Points
• Nursing Continuing Education Credits
• Pharmacy Continuing Education Credits
• Official Completion Certificates
• HFSA Membership
• Original Conference Registration
• Publisher On-Demand Platform Access
• Official HFSA Accounts
• Publisher-Hosted Educational Extras

Why This Course Is Relevant

The Heart Failure Society of America Annual Scientific Meeting 2026 provides a broad educational overview of contemporary heart failure science and clinical practice. Its scientific scope encompasses pharmacotherapy, cardiogenic shock, mechanical support, transplantation, cardiomyopathies, cardiorenal-metabolic medicine, electrophysiology, digital health, and multidisciplinary care. The conference is especially relevant to heart failure specialists, general cardiologists, interventional cardiologists, electrophysiologists, cardiovascular surgeons, nephrologists, and other healthcare professionals involved in heart failure management. The integration of late-breaking scientific research and practical clinical education supports understanding of new developments affecting the treatment of patients with heart failure.

Official Program Reference and MedicalAmboss Purchase Scope

Official HFSA Annual Scientific Meeting 2026: https://hfsa.org/asm/hfsa-annual-scientific-meeting-2026 Official 2026 Scientific Schedule: https://hfsa.org/asm/schedule-glance Official 2026 Late-Breaking Clinical Research: https://hfsa.org/asm/late-breaking-clinical-research-2026 These official references describe the original conference, its educational program, scientific research, venue, dates, and attendee access. They do not independently establish the exact inventory of files included in any separately distributed MedicalAmboss product. MedicalAmboss File Scope: This listing describes the educational subject matter for reference. Original conference registration, live attendance, streaming-platform access, CME or other credit, certificates, memberships, apps, accounts, and publisher-hosted extras are not included unless explicitly listed as store files.

Short Description

Heart Failure Society of America Annual Scientific Meeting 2026 provides an extensive scientific and clinical update in heart failure medicine, advanced cardiovascular care, emerging treatments, mechanical circulatory support, cardiomyopathies, and transplantation. Held October 9–12, 2026, in Phoenix, Arizona, the original HFSA meeting includes expert scientific presentations, case-based education, multidisciplinary discussions, and late-breaking clinical research.

Topics

Track 1: Chronic Heart Failure & Guideline-Directed Medical Therapy (GDMT)

• Rapid Sequencing and Optimization of the Four Pillars of HFrEF Therapy (ARNI, Beta-Blockers, MRA, SGLT2i)
• Diagnostic Algorithms and Phenotype-Specific Management of HFpEF and HFmrEF
• Management of Heart Failure with Improved Ejection Fraction (HFimpEF)
• Overcoming Therapeutic Inertia: Strategies for Titrating GDMT in Outpatient and Inpatient Settings
• Novel Pharmacotherapies in Clinical Trials: Soluble Guanylate Cyclase Stimulators, Cardiac Myosin Activators/Inhibitors, and Anti-Inflammatory Agents
• Managing Worsening Heart Failure (WHF) Events in the Ambulatory Setting

Track 2: Acute Heart Failure, Cardiogenic Shock & Critical Care Cardiology

• Contemporary Classification and Staging of Cardiogenic Shock (SCAI Shock Stages)
• Invasive Hemodynamic Assessment and Pulmonary Artery Catheterization in the Cardiac Intensive Care Unit (CICU)
• Decongestion Strategies in Acute Decompensated Heart Failure: Diuretic Resistance, Sequential Nephron Blockade, and Ultrafiltration
• Temporary Mechanical Circulatory Support (tMCS): Intra-Aortic Balloon Pump (IABP), Impella, TandemHeart, and VA-ECMO
• Shock Team Protocols, Regionalized Networks, and Escalation/De-escalation Algorithms
• Management of Right Ventricular Failure in the Critically Ill Patient

Track 3: Advanced Heart Failure, Durable MCS & Heart Transplantation

• Patient Selection and Timing of Referral for Advanced Heart Failure Therapies
• Durable Left Ventricular Assist Devices (LVAD): Hemocompatibility, Pump Thrombosis, GI Bleeding, and Driveline Infections
• Advances in Heart Transplantation: Donor Pool Expansion, Donation After Circulatory Death (DCD), and Ex Vivo Organ Perfusion
• Contemporary Immunosuppression Regimens and Desensitization Strategies in Sensitized Transplant Candidates
• Non-Invasive Surveillance for Cardiac Allograft Rejection: Donor-Derived Cell-Free DNA (dd-cfDNA) and Gene Expression Profiling
• Prevention, Diagnosis, and Management of Cardiac Allograft Vasculopathy (CAV)

Track 4: Cardiomyopathies, Myocarditis & Genetic Heart Disease

• Transthyretin Cardiac Amyloidosis (ATTR-CM): Non-Invasive Diagnosis, TTR Stabilizers, Silencers, and Emerging Depleters
• Hypertrophic Cardiomyopathy (HCM): Integration of Cardiac Myosin Inhibitors, Septal Reduction Therapy, and Sudden Death Risk Stratification
• Inflammatory Cardiomyopathies: Diagnostic Imaging and Immunosuppression in Cardiac Sarcoidosis and Giant Cell Myocarditis
• Acute and Fulminant Myocarditis: Etiologies, Endomyocardial Biopsy Indications, and Long-Term Sequelae
• Genetic Testing and Cascade Screening in Dilated, Arrhythmogenic, and Non-Compaction Cardiomyopathies
• Peripartum Cardiomyopathy and Cardio-Obstetrics: Risk Stratification and Management Across Pregnancy
• Cardio-Oncology: Prevention, Surveillance, and Management of Cancer Therapy-Related Cardiac Dysfunction (CTRCD)

Track 5: Cardiorenal-Metabolic Syndrome & Comorbidities

• The Cardiorenal-Metabolic Axis: Interplay Between Heart Failure, Chronic Kidney Disease (CKD), Diabetes, and Obesity
• GLP-1 Receptor Agonists and Dual GIP/GLP-1 Agonists in Obesity-Related HFpEF
• Managing Hyperkalemia and Worsening Renal Function During RAASi and MRA Therapy
• Diagnosis and Treatment of Iron Deficiency and Anemia in Heart Failure: Intravenous Iron Supplementation
• Sleep-Disordered Breathing (Obstructive and Central Sleep Apnea) in Heart Failure

Track 6: Pulmonary Hypertension & Right Heart Failure

• Differentiating Pulmonary Arterial Hypertension (PAH – Group 1) from Pulmonary Hypertension Due to Left Heart Disease (PH-LHD – Group 2)
• Invasive Hemodynamic Exercise Testing in Unexplained Dyspnea and Combined Pre- and Post-Capillary PH (CpcPH)
• Targeted Pulmonary Vasodilator Therapies and Emerging Activin Signaling Inhibitors
• Comprehensive Evaluation and Management of Isolated Right Ventricular Failure and Tricuspid Regurgitation

Track 7: Electrophysiology, Devices & Structural Heart Interventions in Heart Failure

• Atrial Fibrillation in Heart Failure: Catheter Ablation vs. Medical Therapy and Rate/Rhythm Control
• Ventricular Arrhythmias in Ischemic and Non-Ischemic Cardiomyopathy: ICD Indications and Catheter Ablation
• Advances in Pacing: Cardiac Resynchronization Therapy (CRT), His-Bundle Pacing, and Left Bundle Branch Area Pacing (LBBAP)
• Neuromodulation and Device-Based Therapies: Cardiac Contractility Modulation (CCM) and Baroreflex Activation Therapy (BAT)
• Transcatheter Edge-to-Edge Repair (TEER) and Transcatheter Valve Replacement for Secondary Mitral and Tricuspid Regurgitation
• Implantable Hemodynamic Monitors and Remote Dielectric Sensing for Guiding Heart Failure Therapy

Track 8: Multidisciplinary Care, Digital Health, Health Equity & Palliative Care

• Artificial Intelligence, Machine Learning, and Wearable Technologies in Heart Failure Prediction and Monitoring
• Optimizing Transitions of Care, Post-Discharge Clinics, and Hospital-at-Home Models
• Addressing Social Determinants of Health (SDOH) and Disparities in Heart Failure Outcomes and Transplant Allocation
• Exercise Training, Cardiac Rehabilitation, and Nutritional Interventions in Heart Failure
• Shared Decision-Making, Advance Care Planning, Symptom Management, and Palliative Care in End-Stage Heart Failure